Ocular Therapeutix (OCUL) & Soleno Therapeutics (SLNO) Head to Head Comparison
Soleno Therapeutics (NASDAQ: SLNO) and Ocular Therapeutix (NASDAQ:OCUL) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, valuation, dividends, profitability, earnings and institutional ownership.
Volatility & Risk
Soleno Therapeutics has a beta of 5.99, indicating that its stock price is 499% more volatile than the S&P 500. Comparatively, Ocular Therapeutix has a beta of 1.32, indicating that its stock price is 32% more volatile than the S&P 500.
This is a breakdown of current recommendations and price targets for Soleno Therapeutics and Ocular Therapeutix, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Soleno Therapeutics currently has a consensus target price of $8.00, indicating a potential upside of 396.89%. Ocular Therapeutix has a consensus target price of $20.67, indicating a potential upside of 327.00%. Given Soleno Therapeutics’ stronger consensus rating and higher possible upside, equities analysts clearly believe Soleno Therapeutics is more favorable than Ocular Therapeutix.
This table compares Soleno Therapeutics and Ocular Therapeutix’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider & Institutional Ownership
52.9% of Ocular Therapeutix shares are held by institutional investors. 69.8% of Soleno Therapeutics shares are held by company insiders. Comparatively, 26.1% of Ocular Therapeutix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Valuation and Earnings
This table compares Soleno Therapeutics and Ocular Therapeutix’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Soleno Therapeutics||$1.45 million||11.10||-$12.06 million||($2.05)||-0.79|
|Ocular Therapeutix||$1.89 million||75.39||-$44.70 million||($2.28)||-2.12|
Soleno Therapeutics has higher earnings, but lower revenue than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Soleno Therapeutics, indicating that it is currently the more affordable of the two stocks.
Soleno Therapeutics beats Ocular Therapeutix on 9 of the 13 factors compared between the two stocks.
Soleno Therapeutics Company Profile
Soleno Therapeutics, Inc., formerly Capnia, Inc., is a healthcare company that develops and commercializes neonatology devices and diagnostics. The Company also has a therapeutics platform based on its proprietary technology for precision metering of gas flow. The Company offers products, such as CoSense end-tidal carbon monoxide (ETCO) Monitor, NeoPIP Infant Resuscitator and Accessories, and Serenz Nasal Relief. The Company has developed the CoSense End-Tidal Carbon Monoxide Monitor that measures ETCO for the detection of dangerous hemolysis rates. The Infant Solutions product line, including the NeoPIP Infant Resuscitator Unit and accessories, is designed for controlled and accurate resuscitation of neonates and infants in the clinical environment. Serenz Nasal Relief is a hand-held nasal irrigator that uses carbon dioxide (CO2) gas to wash the nasal passages.
Ocular Therapeutix Company Profile
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Its lead product candidate, DEXTENZA (dexamethasone insert) for intracanalicular use, has completed Phase III clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. OTX-TP (travoprost insert) is in Phase III clinical development for glaucoma and ocular hypertension. Its earlier stage assets include OTX-TIC, a sustained release travoprost intracameral injection for the treatment of moderate to severe glaucoma and ocular hypertension, as well as sustained release intravitreal injections for the treatment of retinal diseases. These injections include the development of OTX-TKI, a tyrosine kinase inhibitor, and, in collaboration with Regeneron an extended release protein-based anti-vascular endothelial growth factor trap.
Receive News & Stock Ratings for Soleno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soleno Therapeutics and related stocks with our FREE daily email newsletter.